Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the positivity rate of respiratory syncytial virus (RSV), influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in high-risk participants presenting with acute respiratory infections (ARIs) in outpatient settings during the influenza/RSV season and to evaluate the association between lower respiratory tract disease (LRTD) and ARI-related hospitalization in participants positive for RSV.


Clinical Trial Description

Lower respiratory tract infections (LRTIs) are a major cause of mortality and morbidity worldwide with 2.3 million deaths in 2016 alone among all age groups, making it the sixth leading cause of mortality. The current study aims to assess the burden of RSV infections among adult participants presenting in outpatient settings, who are at high risk of complications or progression to severe disease due to their age or pre-existing comorbidities. Regional data from the United States (US), Europe, Middle East, and Asia (EMEA) and Asia-Pacific (APAC) will provide evidence on local RSV morbidity, mortality, medical resource utilization (MRU), standard of care, and quality of life in adults participants. A subset of participants positive for influenza virus and/or SARS-CoV-2 will also be enrolled, to allow for a comparative assessment of disease burden between the 3 viral respiratory pathogens. No study drug will be involved in this study. The total duration of the study for each participant will be a maximum of 3 months (+-1 week) from the date of enrollment. Safety will be assessed in the form of adverse events and serious adverse events related to study devices or procedures and for deaths regardless of causality. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05148780
Study type Interventional
Source Janssen Research & Development, LLC
Contact
Status Completed
Phase Early Phase 1
Start date December 20, 2021
Completion date February 22, 2023

See also
  Status Clinical Trial Phase
Completed NCT03943654 - Improving Nighttime Access to Care and Treatment (Part 2)
Completed NCT05269290 - Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections Phase 3
Not yet recruiting NCT05902702 - Isotonic Saline for Children With Bronchiolitis N/A
Not yet recruiting NCT04525118 - Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-based Study Platform
Completed NCT01431469 - Efficacy and Tolerance of a Follow-On Formula Fed to Children From 12-48 Months of Age in Salvador, Bahia, Brazil N/A
Completed NCT00981513 - Direct and Indirect Benefits of Influenza Vaccination in Schools and Households Phase 4
Recruiting NCT06183229 - Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza Phase 3
Completed NCT03274310 - FluSAFE: Flu SMS Alerts to Freeze Exposure N/A
Completed NCT03736096 - Molecular Diagnosis of Respiratory Viral Infections on Sputum From Cystic Fibrosis Patients
Completed NCT03189537 - Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections Phase 3
Completed NCT03028077 - Effects of GS-3K8 and GINst15 on Acute Respiratory Illness N/A
Enrolling by invitation NCT01286285 - Surveillance of Influenza in Paediatric Intensive Care Units in Bavaria N/A
Completed NCT03840135 - Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI Phase 3
Completed NCT01488435 - Efficacy and Tolerance of a Follow-On Formula Fed to Children From 36-48 Months of Age N/A
Not yet recruiting NCT00545961 - Middle Meatal Bacteriology During Acute Respiratory Infection in Children Phase 4
Completed NCT05273619 - Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection Phase 3
Recruiting NCT04415827 - Energy Supply in Athletes and Untrained Persons With Bronchopulmonary Diseases N/A
Completed NCT03459391 - Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers Phase 1
Withdrawn NCT04938323 - Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly Phase 2/Phase 3
Completed NCT01693380 - Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza Phase 4